Williams Jones & Associates LLC decreased its holdings in GlaxoSmithKline PLC (NYSE:GSK) by 23.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,000 shares of the pharmaceutical company’s stock after selling 2,475 shares during the period. Williams Jones & Associates LLC’s holdings in GlaxoSmithKline PLC were worth $345,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also bought and sold shares of GSK. Russell Investments Group Ltd. acquired a new position in shares of GlaxoSmithKline PLC in the first quarter worth $578,000. Oxford Asset Management grew its stake in shares of GlaxoSmithKline PLC by 491.5% in the first quarter. Oxford Asset Management now owns 59,912 shares of the pharmaceutical company’s stock worth $2,526,000 after acquiring an additional 49,784 shares in the last quarter. Wealthsource Partners LLC acquired a new position in shares of GlaxoSmithKline PLC in the first quarter worth $219,000. Clifford Swan Investment Counsel LLC grew its stake in shares of GlaxoSmithKline PLC by 6.2% in the first quarter. Clifford Swan Investment Counsel LLC now owns 8,715 shares of the pharmaceutical company’s stock worth $367,000 after acquiring an additional 510 shares in the last quarter. Finally, Bronfman E.L. Rothschild L.P. grew its stake in shares of GlaxoSmithKline PLC by 45.4% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 2,410 shares of the pharmaceutical company’s stock worth $102,000 after acquiring an additional 753 shares in the last quarter. Institutional investors and hedge funds own 9.28% of the company’s stock.

Shares of GlaxoSmithKline PLC (NYSE GSK) opened at 40.51 on Friday. GlaxoSmithKline PLC has a 52-week low of $37.20 and a 52-week high of $44.54. The stock has a market capitalization of $99.01 billion, a PE ratio of 39.25 and a beta of 1.03. The stock’s 50 day moving average is $40.03 and its 200 day moving average is $41.65.

GlaxoSmithKline PLC (NYSE:GSK) last released its quarterly earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.70 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.68 by $0.02. The business had revenue of $9.36 billion during the quarter, compared to analyst estimates of $9.52 billion. GlaxoSmithKline PLC had a net margin of 6.48% and a return on equity of 114.93%. Equities research analysts expect that GlaxoSmithKline PLC will post $2.87 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 12th. Investors of record on Friday, August 11th will be issued a dividend of $0.491 per share. This represents a $1.96 dividend on an annualized basis and a yield of 4.83%. This is a positive change from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. The ex-dividend date of this dividend is Wednesday, August 9th. GlaxoSmithKline PLC’s dividend payout ratio (DPR) is presently 197.00%.

WARNING: “Williams Jones & Associates LLC Reduces Holdings in GlaxoSmithKline PLC (GSK)” was first posted by Watch List News and is owned by of Watch List News. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.watchlistnews.com/williams-jones-associates-llc-reduces-holdings-in-glaxosmithkline-plc-gsk/1612855.html.

GSK has been the subject of several research reports. Zacks Investment Research downgraded shares of GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research note on Friday, July 21st. J P Morgan Chase & Co restated a “neutral” rating on shares of GlaxoSmithKline PLC in a research note on Monday, July 24th. BidaskClub downgraded shares of GlaxoSmithKline PLC from a “sell” rating to a “strong sell” rating in a research note on Monday, July 24th. Morgan Stanley downgraded shares of GlaxoSmithKline PLC from an “equal weight” rating to an “underweight” rating in a research note on Friday, September 8th. Finally, Argus restated a “buy” rating and issued a $50.00 price target on shares of GlaxoSmithKline PLC in a research note on Thursday, August 31st. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and seven have issued a buy rating to the company’s stock. GlaxoSmithKline PLC currently has a consensus rating of “Hold” and a consensus price target of $44.67.

About GlaxoSmithKline PLC

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline PLC (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.